Spirulina for liver protection after bile duct cancer surgery
Part of Cancer clinical trials.
This trial tests whether spirulina (a type of algae) can help protect the liver and aid recovery after surgery for bile duct cancer. Participants will take spirulina or a placebo before and after a planned liver resection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with bile duct cancer (cholangiocarcinoma).
- Your liver function should be good enough to be classified as Child-Pugh Class A (a standard measure of liver health).
- You need to be scheduled for a specific treatment plan: chemotherapy (gemcitabine + oxaliplatin), targeted therapy (lenvatinib), and immunotherapy (a PD-1 inhibitor), followed by surgery to remove about half of your liver.
- You must be between 18 and 75 years old and willing to take spirulina or a placebo daily for 3 weeks before and 3 weeks after surgery.
- You cannot have any other active cancer, severe health problems (like uncontrolled heart or lung disease), or a history of liver surgery.
- You must not be allergic to spirulina or have a serious mental health condition that could affect participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
This trial tests a specific chemotherapy after surgery for people with stage II or III bile duct, gallbladder, or ampullary cancer. It may help reduce the chance of cancer coming back.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (gemcitabine, cisplatin, S-1) given before surgery for patients with bile duct cancer that is high-risk for return or has come back within 6 months after a prior surgery. The goal is to see if this treatment can improve outcomes.
This trial tests whether phycocyanin, a natural supplement, can protect the liver before and after surgery to remove part of the liver. It is for people with a type of bile duct cancer who are already getting chemotherapy and other treatments before surgery.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.